Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

Core Insights - Amplia Therapeutics Limited is set to present updated data from the ACCENT trial at the ASCO Gastrointestinal Cancers Symposium, focusing on the combination of Narmafotinib with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer [1][2] Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in Focal Adhesion Kinase (FAK) inhibitors aimed at treating cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer [2] - FAK is recognized as a significant target in cancer treatment and is also involved in chronic diseases like idiopathic pulmonary fibrosis (IPF) [2] Drug Information - Narmafotinib (AMP945) is a potent and selective FAK inhibitor, currently in clinical trials, showing promising results in preclinical studies [3] - The ACCENT trial has achieved a confirmed response rate of 35%, surpassing the 23% response rate from the benchmark MPACT study for gemcitabine and Abraxane alone, with an interim median progression-free survival (PFS) of 7.6 months [3] - A second trial, AMPLICITY, is underway, investigating the combination of Narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients [3]